Eli Lilly and Company (FRA:LLY)

Germany flag Germany · Delayed Price · Currency is EUR
650.00
+31.90 (5.16%)
At close: Sep 30, 2025
5.16%
Market Cap555.95B
Revenue (ttm)45.35B
Net Income (ttm)11.75B
Shares Outn/a
EPS (ttm)13.02
PE Ratio47.31
Forward PE25.85
Dividend5.29 (0.86%)
Ex-Dividend DateAug 15, 2025
Volume397
Average Volume468
Open617.10
Previous Close618.10
Day's Range616.70 - 650.00
52-Week Range537.40 - 888.80
Betan/a
RSI44.00
Earnings DateOct 30, 2025

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]

Industry Pharmaceutical Preparations
Founded 1876
Employees 47,000
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol LLY
Full Company Profile

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD Financial Statements

News

Eli Lilly: Strong Buy On Sustained Growth, Expanding Moat, And Pipeline Depth

Eli Lilly's valuation has compressed significantly from last year's highs, despite fundamentals improving faster than its share price. Industry-leading incretin treatments (Mounjaro, Zepbound) are dri...

1 day ago - Seeking Alpha

LLY Stock Set For A 20% Breakout?

Eli Lilly stock (NYSE: LLY) should be on your radar. Here's why – it is presently trading within the support range ($688 – $761), price points from which it has previously bounced significantly.

1 day ago - Forbes

Novo, Lilly Weight-Loss Drugs May Help Alzheimer's Patients. What It Means for the Stocks.

The blockbuster medications could open a new frontier for the pharma giants.

1 day ago - Barrons

Pharma tariffs 'not a huge risk' for domestic companies, says Mizuho's Jared Holz

CNBC's “Fast Money” team discusses the potential impact of pharmaceutical tariffs with Jared Holz, healthcare equity strategist at Mizuho.

4 days ago - CNBC Television

Many pharma companies already made U.S. investment promises, says Citi's Geoff Meacham

CNBC's “Closing Bell Overtime” team discusses President Trump's plan to impose a 100% tariff on “all any branded or patented Pharmaceutical Product” entering the U.S. with Geoff Meacham of Citi Resear...

4 days ago - CNBC Television

A New Prescription For Pain: Understanding Trump's 100% Pharma Tariff

Novo Nordisk, Sanofi, and AstraZeneca face the largest dollar exposure to President Trump's new 100% tariff on imported branded drugs. NVO's heavy reliance on U.S. sales and imported GLP-1 products pu...

4 days ago - Seeking Alpha

Pharma tariffs still have a lot of questions outstanding, says Bernstein's Courtney Breen

Courtney Breen, Bernstein senior analyst, joins 'The Exchange' to discuss the companies exempt from pharma tariffs, the country's with existing trade deals and much more.

4 days ago - CNBC Television

Portal Innovations' John Flavin: Tariffs on pharma could raise costs and delay drug access

John Flavin, Portal Innovations founder and CEO, joins CNBC's 'Squawk on the Street' to discuss the Trump administration's proposed pharmaceutical tariffs, the impact on biotech startups and clinical ...

4 days ago - CNBC Television

Lilly opens newest Gateway Labs site in San Diego to boost local biotechnology ecosystem

New 82,514 square foot facility will accommodate up to 15 biotech companies to fuel next-generation medicines  Gateway Labs model provides flexible lab space and tailored scientific engagement to supp...

4 days ago - PRNewsWire

Eli Lilly, Pfizer Stocks Rise After Trump's 100% Pharma Tariff Threat. Here's Why.

Trump's threat of a 100% tariff on imported branded or patented drugs sounds dramatic, yet, pharma stocks were mostly in the green as the past few months have already seen a flurry of companies announ...

4 days ago - Barrons

Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease

Approved for earliest symptomatic stages of disease, demonstrating significant slowing of cognitive and functional decline Only therapy with evidence to support completing course of treatment once amy...

5 days ago - PRNewsWire

US FDA approves Eli Lilly's therapy for metastatic breast cancer

Eli Lilly said on Thursday that the U.S. Food and Drug Administration has approved its therapy for the treatment of metastatic breast cancer in patients whose disease progressed after at least one lin...

5 days ago - Reuters

U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer

An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor In the Phase 3 EMBER-3 trial, Inluriyo monotherap...

5 days ago - PRNewsWire

Eli Lilly and Company (LLY) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript

Eli Lilly and Company (NYSE:LLY) Bernstein 2nd Annual Global Healthcare Conference September 25, 2025 8:00 AM EDT Company Participants Lucas Montarce - Executive VP & CFO Mike Czapar - Director of In...

5 days ago - Seeking Alpha

Eli Lilly: Buying The Dip With Confidence

Eli Lilly (LLY) remains a strong growth company, driven by leadership in the booming GLP-1 and diabetes drug markets despite recent share price weakness. LLY's aggressive investments in manufacturing,...

5 days ago - Seeking Alpha

Eli Lilly halts trial of experimental weight-loss drug

Eli Lilly has halted a study of an experimental drug, which is designed to prevent obesity patients from losing too much muscle, due to strategic business reasons, according to a U.S. registry of clin...

5 days ago - Reuters

Lilly plans to launch its experimental weight-loss pill in India, exec says

Eli Lilly plans to bring its experimental oral weight-loss drug orforpligron in India as it sees scope for such products in the world's most populous nation, a senior executive said on Thursday.

5 days ago - Reuters

The Big 3: AVGO, LLY, GS

@Theotrade's Don Kaufman is back on Big 3 — and is bearish on all of today's stocks. He points to exuberant A.I.

6 days ago - Schwab Network

Eli Lilly's boss calls UK the 'worst' European country for drug prices

Eli Lilly Chief Executive Dave Ricks said Britain was "probably the worst country in Europe" for drug prices in an interview with the Financial Times, intensifying pressure on the government to improv...

6 days ago - Reuters

Eli Lilly to Build $6.5 Billion Ingredient-Manufacturing Facility in Texas

The planned site, which will be used to manufacture the company's first oral weight-loss drug, is expected to be operational within five years.

7 days ago - WSJ

Eli Lilly to make weight-loss pill in new $6.5 billion Texas plant

Eli Lilly will make its next-generation experimental weight-loss pill, orforglipron, at a new multi-billion-dollar manufacturing plant it plans to build in Texas, the company said on Tuesday.

7 days ago - Reuters

Eli Lilly to build $6.5 billion Texas manufacturing facility for obesity pill, other drugs

Eli Lilly said it will spend $6.5 billion to build a manufacturing facility in Houston, Texas, to boost production of the company's pipeline of small molecule drugs, including its closely watched expe...

7 days ago - CNBC

Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas

The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines  Company plans to create 4,615 manufactur...

7 days ago - PRNewsWire

Boys & Girls Clubs of America Receives $10 Million Grant from Lilly Endowment Inc. to Help Transform the Future of Youth Programs in and Around Native Communities

Funding will strengthen Boys & Girls Clubs serving youth who live on or near federal and state designated Native lands through program support, leadership development and digital transformation Fundin...

7 days ago - GlobeNewsWire

Celltrion unit pays $330 million for Eli Lilly production facility, filing shows

Celltrion Inc. said in a regulatory filing in South Korea on Tuesday its U.S. subsidiary has acquired Imclone Systems LLC from Eli Lilly in the United States for $330 million.

7 days ago - Reuters